ArticleJournal of diabetes and metabolic disorders2025
Overbasalization and glycemic control: longitudinal analysis in people with type 2 diabetes in Peru.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate the longitudinal association between overbasalization and glycemic control. Methods: Retrospective cohort study including subjects with T2DM diagnosis, insulin users and treated in the Endocrinology Service of EsSalud through the National Telemedicine Center, part of the Social Security (EsSalud) in Lima, Peru. Data was taken from January 2023 to December 2024, and only those with at least two assessments were considered. Hospitalized participants, chronic users of corticosteroids, those with transfusions, and pregnant women during the study period were excluded. The dependent variable was glycemic control, defined using glycated hemoglobin (HbA1c < 53 mmol/mol [< 7%] or ≥ 53mmol/mol [≥ 7%]), while the independent variable was overbasalization, defined as a basal insulin dose > 0.5 IU/Kg/day. The association of interest was evaluated cross-sectionally and longitudinally. Results: A total of 398 records, mean age of 63.8 (SD: 10.4) years and 50.8% women, was analyzed. The mean duration of diabetes was 15.8 (SD: 8.7) years, whereas the median duration of insulin use was 3.3 (interquartile range: 6) years. The prevalence of overbasalization at the cohort baseline was 43.4%, whereas only 14.5% had appropriate glycemic control. In cross-sectional analysis, no association of overbasalization with glycemic control was found; however, in the longitudinal analysis (mean: 9.6 [SD: 3.5] months of follow-up), the group with overbasalization had a 42% reduction (95% CI: 20% - 58%) in the probability of having appropriate glycemic control. Conclusions: Among insulin users, overbasalization was observed to be associated with reduced glycemic control and higher HbA1c levels. More than 40% of insulin users had overbasalization at the cohort baseline. Our study suggests that overbasalization is frequent among people using insulin and should be evaluated to optimize glycemic control. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01756-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.